Skip to main content

Universe Pharmaceuticals Inc. (UPC)

NASDAQ Stock Market Healthcare Drug Manufacturers - Specialty & GenericView data quality →
49.6Fair

ValueMarkers Composite Index

Top 27%#32,601 of 44,714
Undervalued

100% below intrinsic value ($6,833)

UndervaluedFair ValueOvervalued
Piotroski
4/9
Neutral
Beneish
-2.43
Low Risk
Altman
0.62
Distress
DCF Value
$6,833
Undervalued
ROIC
-4.5%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Universe Pharmaceuticals Inc. (UPC) — VMCI valuation read

Universe Pharmaceuticals Inc. sits at VMCI 50/100, with the Healthcare sector median at 50. That 0-point spread is the first thing to note on UPC: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on UPC are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on UPC: UPC trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 0.6x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

UPC fell 2.8% over the trailing 7 days, with a -19.9% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in UPC’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.